特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

PoC (ポイントオブケア) 診断の市場:市場規模・シェア・動向分析、部門別予測 (製品別 (血糖検査、血中ガス/電解質、がんマーカー)・エンドユース別 (診療所、病院)・地域別)

Point of Care Diagnostics Market Size, Share & Trends Analysis Report By Product (Glucose Testing, Blood Gas/ Electrolytes, Cancer Marker), By End Use (Clinics, Hospital), By Region, And Segment Forecasts, 2020 - 2027

発行 Grand View Research, Inc. 商品コード 608208
出版日 ページ情報 英文 250 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=106.61円で換算しております。
PoC (ポイントオブケア) 診断の市場:市場規模・シェア・動向分析、部門別予測 (製品別 (血糖検査、血中ガス/電解質、がんマーカー)・エンドユース別 (診療所、病院)・地域別) Point of Care Diagnostics Market Size, Share & Trends Analysis Report By Product (Glucose Testing, Blood Gas/ Electrolytes, Cancer Marker), By End Use (Clinics, Hospital), By Region, And Segment Forecasts, 2020 - 2027
出版日: 2020年03月05日 ページ情報: 英文 250 Pages
概要

世界のPoC (ポイントオブケア) 診断の市場規模は今後、3.2%のCAGRで成長し、2027年までに241億米ドルに達すると予測されています。

マイクロ流体システムをベースとした高感度で高感度な小型バイオセンサーの開発とハンドヘルドデバイスの継続的な進歩が、市場を牽引すると予想されています。これらのシステムは、十分な訓練を受けた専門家がいない分野での使用に適した、自動化、統合、および多重検出が可能です。

当レポートでは、世界のPoC (ポイントオブケア) 診断および検査薬の市場について分析し、市場の基本構造や主な促進・抑制要因、製品別・エンドユース別・地域別の市場動向見通し (過去3年間・今後9年間分)、主要企業のプロファイルと戦略展開状況、といった情報を取りまとめてお届けいたします。

第1章 エグゼクティブサマリー

第2章 調査手法

第3章 市場の変動要因・傾向・範囲

  • 市場の定義と範囲
  • 製品普及率・成長率の見通し:マッピング
  • ポイントオブケア診断/テストSWOT分析、要因別(政治および法務、経済および技術)
  • 業界分析:ポーターのファイブフォース分析
  • 主な資本取引・戦略的提携の分析
  • PoC診断薬・検査薬:価格・費用・利益率の分析
  • PoC診断薬・検査薬:市場への影響力
  • 製品ポジショニング分析
  • マーケティングチャネル
  • 米国のPoC診断薬市場:規制体制の分析
  • 欧州のPoC診断薬市場:規制体制の分析
  • 日本のPoC診断薬市場:規制体制の分析

第4章 競争分析

  • 近年の動向と影響度の分析:主要企業の場合
  • 企業の分類
  • 各企業のの市場ポジション分析
  • 市場の差別化要因
  • 新規参入企業/新規企業

第5章 PoC診断薬・検査薬市場:製品別の推定と動向分析

  • PoC診断薬・検査薬市場:製品別の動向分析
  • PoC診断薬・検査薬
  • Hb1Ac検査
  • PoC凝固診断・検査
  • PoC不妊診断・検査
  • PoC感染症診断・検査
    • HIV
    • クロストリジウムディフィシル
    • HBV PoC検査
    • 肺炎/連鎖球菌関連感染症
    • RSV (呼吸系発疹ウイルス) PoC診断・検査
    • HPVポイントオブケア診断/テスト
    • インフルエンザPoC診断・検査
    • HCV PoC診断・検査
    • MRSA PoC診断・検査
    • 結核/薬剤耐性結核のPoC診断・検査
    • HSV PoC診断・検査
    • その他の感染症のPoC診断・検査
  • PoC診断・検査用心臓マーカー
  • 甲状腺検査用PoC診断・検査
  • 血液PoC診断・検査
  • プライマリケアシステム
  • 分散型臨床化学PoC診断・検査 ポイントオブケア診断/テスト
  • 排泄POC検査
  • 脂質POC
  • がんマーカー
  • 血液ガス/電解質
  • 外来治療用化学薬品
  • 薬物乱用PoC診断・検査
  • 尿検査PoC診断・検査

第6章 PoC診断薬・検査薬市場:エンドユース別の推定と動向分析

  • PoC診断薬・検査薬市場:最終用途別の動向分析
  • クリニック
    • 薬局・リテールクリニック
    • 診療所
    • 外来治療施設
    • ナースプラクティショナー (診療看護師)
  • 病院
  • 在宅治療
  • 介護施設
  • 実験室

第7章 PoC診断薬・検査薬市場:地域別の推定と動向分析

  • PoC診断薬・検査薬市場:地域別の市場シェア (最新値・予測値)
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第8章 競争環境

  • 企業プロファイル
図表

List of Tables

  • TABLE 1 Examples: CLIA waived tests
  • TABLE 2 North America diabetes prevalence (national prevalence %), 2013 & 2035
  • TABLE 3 Europe diabetes prevalence (national prevalence %), 2013 & 2035
  • TABLE 4 Asia Pacific diabetes prevalence (national prevalence %), 2013 & 2035
  • TABLE 5 Latin America Diabetes Prevalence (national prevalence %), 2013 & 2035
  • TABLE 6 MEA and Africa diabetes prevalence (national prevalence %), 2013 & 2035
  • TABLE 7 CIS diabetes prevalence (national prevalence %), 2013 & 2035
  • TABLE 8 Point of care solutions, by segment
  • TABLE 9 Description of POC devices for detection of diseases through specific salivary biomarkers.
  • TABLE 10 Methods used for the evaluation of diagnostic toolboxes
  • TABLE 11 Abbott Healthcare: List of wholesalers & distributors
  • TABLE 12 National and international requirements for quality management of point of care diagnostic/testing in France
  • TABLE 13 North America point of care diagnostics/testing market estimates and forecasts, by product, 2016 - 2027 (USD Million)
  • TABLE 14 North America infectious disease point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 15 North America point of care diagnostics/testing market estimates and forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 16 North America clinics point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 17 U.S. point of care diagnostics/testing market estimates and forecasts, by product, 2016 - 2027 (USD Million)
  • TABLE 18 U.S. infectious disease point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 19 U.S. point of care diagnostics/testing market estimates and forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 20 U.S. clinics point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 21 Canada point of care diagnostics/testing market estimates and forecasts, by product, 2016 - 2027 (USD Million)
  • TABLE 22 Canada infectious disease point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 23 Canada point of care diagnostics/testing market estimates and forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 24 Canada clinics point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 25 Europe point of care diagnostics/testing market estimates and forecasts, by product, 2016 - 2027 (USD Million)
  • TABLE 26 Europe infectious disease point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 27 Europe point of care diagnostics/testing market estimates and forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 28 Europe clinics point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 29 Germany point of care diagnostics/testing market estimates and forecasts, by product, 2016 - 2027 (USD Million)
  • TABLE 30 Germany infectious disease point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 31 Germany point of care diagnostics/testing market estimates and forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 32 Germany clinics point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 33 U.K. point of care diagnostics/testing market estimates and forecasts, by product, 2016 - 2027 (USD Million)
  • TABLE 34 U.K. infectious disease point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 35 U.K. point of care diagnostics/testing market estimates and forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 36 U.K. clinics point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 37 Spain point of care diagnostics/testing market estimates and forecasts, by product, 2016 - 2027 (USD Million)
  • TABLE 38 Spain infectious disease point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 39 Spain point of care diagnostics/testing market estimates and forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 40 Spain clinics point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 41 Italy point of care diagnostics/testing market estimates and forecasts, by product, 2016 - 2027 (USD Million)
  • TABLE 42 Italy infectious disease point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 43 Italy point of care diagnostics/testing market estimates and forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 44 Italy clinics point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 45 France point of care diagnostics/testing market estimates and forecasts, by product, 2016 - 2027 (USD Million)
  • TABLE 46 France infectious disease point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 47 France point of care diagnostics/testing market estimates and forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 48 France clinics point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 49 Russia point of care diagnostics/testing market estimates and forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 50 Russia infectious disease point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 51 Russia point of care diagnostics/testing market estimates and forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 52 Russia clinics point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 53 Asia Pacific point of care diagnostics/testing market estimates and forecasts, by product, 2016 - 2027 (USD Million)
  • TABLE 54 Asia Pacific infectious disease point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 55 Asia Pacific point of care diagnostics/testing market estimates and forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 56 Asia Pacific clinics point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 57 Japan point of care diagnostics/testing market estimates and forecasts, by product, 2016 - 2027 (USD Million)
  • TABLE 58 Japan infectious disease point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 59 Japan point of care diagnostics/testing market estimates and forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 60 Japan clinics point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 61 China point of care diagnostics/testing market estimates and forecasts, by product, 2016 - 2027 (USD Million)
  • TABLE 62 China infectious disease point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 63 China point of care diagnostics/testing market estimates and forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 64 China clinics point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 65 India point of care diagnostics/testing market estimates and forecasts, by product, 2016 - 2027 (USD Million)
  • TABLE 66 India infectious disease point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 67 India point of care diagnostics/testing market estimates and forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 68 India clinics point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 69 Korea point of care diagnostics/testing market estimates and forecasts, by product, 2016 - 2027 (USD Million)
  • TABLE 70 Korea infectious disease point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 71 Korea point of care diagnostics/testing market estimates and forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 72 Korea clinics point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 73 Australia point of care diagnostics/testing market estimates and forecasts, by product, 2016 - 2027 (USD Million)
  • TABLE 74 Australia infectious disease point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 75 Australia point of care diagnostics/testing market estimates and forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 76 Australia clinics point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 77 Singapore point of care diagnostics/testing market estimates and forecasts, by product, 2016 - 2027 (USD Million)
  • TABLE 78 Singapore infectious disease point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 79 Singapore point of care diagnostics/testing market estimates and forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 80 Singapore clinics point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 81 Latin America point of care diagnostics/testing market estimates and forecasts, by product, 2016 - 2027 (USD Million)
  • TABLE 82 Latin America infectious disease point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 83 Latin America point of care diagnostics/testing market estimates and forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 84 Latin America clinics point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 85 Brazil point of care diagnostics/testing market estimates and forecasts, by product, 2016 - 2027 (USD Million)
  • TABLE 86 Brazil infectious disease point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 87 Brazil point of care diagnostics/testing market estimates and forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 88 Brazil clinics point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 89 Mexico point of care diagnostics/testing market estimates and forecasts, by product, 2016 - 2027 (USD Million)
  • TABLE 90 Mexico infectious disease point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 91 Mexico point of care diagnostics/testing market estimates and forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 92 Mexico clinics point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 93 Argentina point of care diagnostics/testing market estimates and forecasts, by product, 2016 - 2027 (USD Million)
  • TABLE 94 Argentina infectious disease point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 95 Argentina point of care diagnostics/testing market estimates and forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 96 Argentina clinics point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 97 Chile point of care diagnostics/testing market estimates and forecasts, by product, 2016 - 2027 (USD Million)
  • TABLE 98 Chile infectious disease point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 99 Chile point of care diagnostics/testing market estimates and forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 100 Chile clinics point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 101 MEA point of care diagnostics/testing market estimates and forecasts, by product, 2016 - 2027 (USD Million)
  • TABLE 102 MEA infectious disease point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 103 MEA point of care diagnostics/testing market estimates and forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 104 MEA clinics point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 105 South Africa point of care diagnostics/testing market estimates and forecasts, by product, 2016 - 2027 (USD Million)
  • TABLE 106 South Africa infectious disease point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 107 South Africa point of care diagnostics/testing market estimates and forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 108 South Africa clinics point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 109 Kenya point of care diagnostics/testing market estimates and forecasts, by product, 2016 - 2027 (USD Million)
  • TABLE 110 Kenya infectious disease point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 111 Kenya point of care diagnostics/testing market estimates and forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 112 Kenya clinics point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 113 Nigeria point of care diagnostics/testing market estimates and forecasts, by product, 2016 - 2027 (USD Million)
  • TABLE 114 Nigeria infectious disease point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 115 Nigeria point of care diagnostics/testing market estimates and forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 116 Nigeria clinics point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 117 Saudi Arabia point of care diagnostics/testing market estimates and forecasts, by product, 2016 - 2027 (USD Million)
  • TABLE 118 Saudi Arabia infectious disease point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 119 Saudi Arabia point of care diagnostics/testing market estimates and forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 120 Saudi Arabia clinics point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 121 Zimbabwe point of care diagnostics/testing market estimates and forecasts, by product, 2016 - 2027 (USD Million)
  • TABLE 122 Zimbabwe infectious disease point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 123 Zimbabwe point of care diagnostics/testing market estimates and forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 124 Zimbabwe clinics point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 125 UAE point of care diagnostics/testing market estimates and forecasts, by product, 2016 - 2027 (USD Million)
  • TABLE 126 UAE infectious disease point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 127 UAE point of care diagnostics/testing market estimates and forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 128 UAE clinics point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 129 Qatar point of care diagnostics/testing market estimates and forecasts, by product, 2016 - 2027 (USD Million)
  • TABLE 130 Qatar infectious disease point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)
  • TABLE 131 Qatar point of care diagnostics/testing market estimates and forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 132 Qatar clinics point of care diagnostics/testing market estimates and forecasts, by disease, 2016 - 2027 (USD Million)

List of Figures

  • FIG. 1 Point of care diagnostics: Market summary
  • FIG. 2 Market research process
  • FIG. 3 Information procurement
  • FIG. 4 Primary research pattern
  • FIG. 5 Market research approaches
  • FIG. 6 Value chain based sizing & forecasting
  • FIG. 7 QFD modelling for market share assessment
  • FIG. 8 Point of care diagnostics: Market trends & outlook
  • FIG. 9 Market segmentation & scope
  • FIG. 10 Point of care diagnostics market: Driver relevance analysis (Current & future impact)
  • FIG. 11 Shift in POC molecular diagnostic trends
  • FIG. 12 Global percentage of population, by age group, 2000 and 2050
  • FIG. 13 Population over the age of 65 years, by region, 2010 and 2050
  • FIG. 14 Diabetes prevalence of top 10 countries in 2013 in the age group of 20 to 79 years (million)
  • FIG. 15 Current and projected prevalence of diabetes, by geography, 2013 & 2035 (% increase)
  • FIG. 16 Point of care diagnostics market: Restraint relevance analysis (Current & future impact)
  • FIG. 17 Point of care diagnostics market: Challenge relevance analysis (Current & future impact)
  • FIG. 18 Penetration & growth prospect mapping for point of care end-use, 2019
  • FIG. 19 Point of care diagnostics: SWOT analysis, by factor (political & legal, economic and technological)
  • FIG. 20 Point of care diagnostics: Porter's five forces analysis
  • FIG. 21 Factors impacting market entry strategies
  • FIG. 22 Key market entry methods
  • FIG. 23 Product positioning analysis, 2019
  • FIG. 24 Marketing Channels
  • FIG. 25 Roche Distribution Presence
  • FIG. 26 Instrumentation Laboratory (Werfen Group) distribution presence
  • FIG. 27 Abbott Laboratories distribution network coverage
  • FIG. 28 Alere distribution presence
  • FIG. 29 Siemens distribution presence
  • FIG. 30 Danaher distribution presence (Radiometer, HemoCue, and Beckman Coulter)
  • FIG. 31 Becton Dickinson presence
  • FIG. 32 Recent developments & impact analysis, by key market participants
  • FIG. 33 Company/competition categorization
  • FIG. 34 Competitive landscape Point of care diagnostics/testing- Major market participants
  • FIG. 35 Point of care diagnostics/testing market product outlook key takeaways
  • FIG. 36 Point of care diagnostics/testing market: Product movement analysis
  • FIG. 37 Global point of care glucose diagnostics/testing, 2016 - 2027 (USD Million)
  • FIG. 38 Global point of care Hb1Ac diagnostics/testing, 2016 - 2027 (USD Million)
  • FIG. 39 Global point of care coagulation diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 40 Global POC fertility market, 2016 - 2027 (USD Million)
  • FIG. 41 Global point of care infectious disease diagnostics/testing, 2016 - 2027 (USD Million)
  • FIG. 42 Global HIV point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 43 Global Clostridium difficile point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 44 Global HBV point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 45 Global pneumonia or streptococcus associated infections point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 46 Global respiratory syncytial virus (RSV) point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 47 Global HPV point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 48 Global influenza/flu point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 49 Global HCV point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 50 Global MRSA point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 51 Global TB and drug-resistant TB point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 52 Global HSV point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 53 Global other infectious diseases point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 54 Global POC cardiac markers market, 2016 - 2027 (USD Million)
  • FIG. 55 Global POC thyroid stimulating hormone market, 2016 - 2027 (USD Million)
  • FIG. 56 Global haematology point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 57 Global primary care systems point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 58 Global decentralized clinical chemistry point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 59 Global feces point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 60 Global lipid point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 61 Global cancer marker testing market, 2016 - 2027 (USD Million)
  • FIG. 62 Global blood gas/electrolytes point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 63 Global ambulatory chemistry point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 64 Global drug abuse point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 65 Global urinalysis point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 66 Point of care diagnostics/testing market: End-use outlook key takeaways
  • FIG. 67 Global point of care diagnostics/testing market: End-use movement analysis
  • FIG. 68 Global clinics market, 2016 - 2027 (USD Million)
  • FIG. 69 Global pharmacy & retail clinics market, 2016 - 2027 (USD Million)
  • FIG. 70 Global phsician office market, 2016 - 2027 (USD Million)
  • FIG. 71 Global urgent care clinics market, 2016 - 2027 (USD Million)
  • FIG. 72 Global non-practice clinics market, 2016 - 2027 (USD Million)
  • FIG. 73 Global hospitals market, 2016 - 2027 (USD Million)
  • FIG. 74 Global home point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 75 Global assisted living healthcare facilities testing market, 2016 - 2027 (USD Million)
  • FIG. 76 Global laboratory market, 2016 - 2027 (USD Million)
  • FIG. 77 Point of care diagnostics/testing: Regional market place: Key takeaway
  • FIG. 78 Point of care diagnostics/testing regional outlook, 2019 & 2027
  • FIG. 79 North America POC diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 80 U.S. POC diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 81 Canada POC diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 82 Europe point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 83 Germany point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 84 U.K. point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 85 France point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 86 Italy point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 87 Spain point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 88 Russia point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 89 Asia Pacific point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 90 Japan point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 91 China point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 92 India point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 93 Australia point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 94 Korea point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 95 Singapore point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 96 Latin America point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 97 Brazil point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 98 Mexico point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 99 Argentina point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 100 Chile point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 101 Middle East & Africa. point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 102 South Africa point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 103 Saudi Arabia point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 104 Kenya point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 105 Nigeria point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 106 Zimbabwe point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 107 UAE point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • FIG. 108 Qatar point of care diagnostics/testing market, 2016 - 2027 (USD Million)
目次
Product Code: 978-1-68038-046-0

The global point of care diagnostics market size is expected to reach USD 24.1 billion by 2027, expanding at a CAGR of 3.2%, according to a new report by Grand View Research, Inc. Continuous advancement in the development of highly sensitive and specific miniaturized biosensors, based on microfluidic systems along with handheld devices, is anticipated to drive the market. These systems are capable of automation, integration, and multiplex detection, suitable for use in areas without well-trained professionals.

These tests have emerged as an indispensable part of modern healthcare, as it improves the quality, accuracy, availability, and affordability of patient care. The uptake of POC devices is rapidly progressing due to the incorporation of advanced technologies. For instance, in July 2019, HiberGene Diagnostics has outlined plans to develop a cost-effective POC testing system based on its licensed loop-mediated isothermal amplification technology.

The growing popularity of rapid testing in near-patient settings has positively impacted point of care testing market growth. The rise in investments to develop advanced rapid testing devices, such as single integrated user-friendly devices, fuels market progression. For instance, in February 2019, the Global Health Investment Fund (GHIF) granted USD 6 million to Atomo Diagnostics for the commercialization of its AtomoRapid diagnostic test platform.

Further key findings from the report suggest:

Glucose testing accounted for the largest revenue share owing to the high incidence rate of diabetes and the abundant usage of portable glucose meters

Cancer markers are expected to witness the fastest growth rate due to the extensive ongoing R&D activities related to cancer and growing demand for circulating tumor cells (CTC) - based cancer detection

POC tests offer several benefits as compared to conventional lab tests that lead to their high utilization rate in clinics, resulting in the largest revenue share of clinics

These benefits include reduced turnaround testing timeline, delivery of on-site results, minimal contact with clinical staff, and faster diagnosis

Continuous development of point of care devices, especially glucose meters, for home care settings, early detection, and prevention of diseases is expected to drive the home segment at the fastest growth rate

North America dominated the point of care testing market owing to the favorable government initiatives and programs related to lipid and blood sugar level testing that encourage the usage rate of point of care tests in this region

Key participants operating in this market include Danaher; Abbott Laboratories; bioMerieux SA; Trividia Health, Inc.; QIAGEN, F. Hoffmann-La Roche Ltd.; and Siemens

Companies are adopting several strategic developments related to the development of biosensors for point of care settings

For instance, in September 2019, BioMed X completed its collaboration with Roche Diagnostics for the development of nanomaterial-based biosensors for point of care testing

Table of Contents

Chapter 1 Executive Summary

Chapter 2 Research Methodology

  • 2.1 Information procurement
  • 2.2 Data Analysis

Chapter 3 Market Variables, Trends & Scope

  • 3.1 Market Segmentation & Scope
    • 3.1.1 Market driver analysis
      • 3.1.1.1 Introduction of CLIA waived tests
      • 3.1.1.2 Rise in funding from government and private institutions
      • 3.1.1.3 Growing geriatric population base
      • 3.1.1.4 Growing prevalence of target diseases
      • 3.1.1.5 Growing demand for home healthcare and the introduction of advance technology enabled products
    • 3.1.2 Market restraint analysis
      • 3.1.2.1 High procedure costs coupled with limited adoption of POC devices in certain emerging regions
      • 3.1.2.2 Presence of ambiguous regulatory as well as reimbursement framework for primary care setting
    • 3.1.3 Market challenge analysis
      • 3.1.3.1 POC devices pose challenges in maintaining the quality standards
  • 3.2 Penetration & Growth Prospect Mapping
    • 3.2.1 Penetration & growth prospect mapping for point of care end-use, 2019
  • 3.3 Point of care Diagnostics/Testing SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • 3.4 Industry Analysis - Porter's
  • 3.5 Major Deals & Strategic Alliances Analysis
    • 3.5.1 Joint ventures
    • 3.5.2 Mergers & acquisitions
    • 3.5.3 Licensing & partnership
    • 3.5.4 Market entry strategies
  • 3.6 Price-Cost-Margin Analysis for Point of care Diagnostics/Testing
  • 3.7 Point of care Diagnostics/Testing: Market influencers
    • 3.7.1 High sensitivity
    • 3.7.2 Shift to molecular diagnostics
  • 3.8 Product Positioning Analysis, 2019
    • 3.8.1 Glucose testing
    • 3.8.2 Hb1Ac testing
    • 3.8.3 Coagulation testing
    • 3.8.4 Fertility
    • 3.8.5 Infectious disease
    • 3.8.6 Cardiac markers
    • 3.8.7 Thyroid
    • 3.8.8 Haematology
    • 3.8.9 Primary care
    • 3.8.10 Decentralized clinical chemistry
    • 3.8.11 Faecal
    • 3.8.12 Lipid testing
    • 3.8.13 Cancer marker
    • 3.8.14 Blood gas/electrolytes
    • 3.8.15 Ambulatory chemistry
    • 3.8.16 Drug of Abuse (DOA) testing
    • 3.8.17 Urinalysis
  • 3.9 Marketing Channels
    • 3.9.1 Abbott Laboratories
      • 3.9.1.1 Abbott Laboratories: Marketing channels & distribution network for POC
      • 3.9.1.2 Alere Inc.
      • 3.9.1.2.1 Alere: Marketing channels & distribution network for POC
    • 3.9.2 Roche Diagnostics
      • 3.9.2.1 Roche Diagnostics: Marketing channels & distribution network for POC
    • 3.9.3 Siemens
      • 3.9.3.1 Siemens: Marketing channels & distribution network for POC
    • 3.9.4 Danaher
      • 3.9.4.1 Danaher: Marketing channels & distribution network for POC
    • 3.9.5 Instrumentation Laboratory Spa.
      • 3.9.5.1 Instrumentation Laboratory Spa.: Marketing channels & distribution network for POC
    • 3.9.6 Becton Dickinson
      • 3.9.6.1 Becton Dickinson.: Marketing channels & distribution network for POC
  • 3.10 Regulatory Framework Analysis for U.S. Point of Care Diagnostics
  • 3.11 Regulatory Framework Analysis for Europe Point of Care Diagnostics
  • 3.12 Regulatory Framework Analysis for Japan Point of Care Diagnostics

Chapter 4 Competitive Analysis

  • 4.1 Recent Developments & Impact Analysis, by Key Market Participants
  • 4.2 Company/Competition Categorization
  • 4.3 Company Market Position Analysis
    • 4.3.1 Company size
    • 4.3.2 Distribution network
    • 4.3.3 Product portfolio
    • 4.3.4 Segment coverage
    • 4.3.5 Geographic presence
    • 4.3.6 Collaborations
    • 4.3.7 Conclusion
  • 4.4 Market Differentiators
    • 4.4.1 Application trends
    • 4.4.2 Technology trends
    • 4.4.3 Test location trends
    • 4.4.4 End-use trends
    • 4.4.5 Regional trends
  • 4.5 New Entrants/Emerging players

Chapter 5 Point of care Diagnostics/ Testing Market: Product Estimates & Trend Analysis

  • 5.1 Point of care diagnostics/testing market: Product Movement Analysis
  • 5.2 Point of care Glucose Diagnostics/Testing
    • 5.2.1 Global point of care glucose diagnostics/testing, 2016 - 2027 (USD Million)
  • 5.3 Hb1Ac Testing.
    • 5.3.1 Global point of care Hb1Ac diagnostics/testing, 2016 - 2027 (USD Million)
  • 5.4 Point of care Coagulation Diagnostics/Testing
    • 5.4.1 Global point of care coagulation diagnostics/testing market, 2016 - 2027 (USD Million)
  • 5.5 Point of care Fertility Diagnostics/Testing
    • 5.5.1 Global point of care fertility diagnostics/testing, 2016 - 2027 (USD Million)
  • 5.6 Point of care Infectious Disease Diagnostics/Testing
    • 5.6.1 Global point of care infectious disease diagnostics/testing, 2016 - 2027 (USD Million)
    • 5.6.2 HIV POC testing
      • 5.6.2.1 Global HIV point of care diagnostics/testing market, 2016 - 2027 (USD Million)
    • 5.6.3 Clostridium difficile point of care diagnostics/testing
      • 5.6.3.1 Global Clostridium difficile point of care diagnostics/testing market, 2016 - 2027 (USD Million)
    • 5.6.4 HBV POC testing point of care diagnostics/testing
      • 5.6.4.1 Global HBV point of care diagnostics/testing market, 2016 - 2027 (USD Million)
    • 5.6.5 Pneumonia or streptococcus associated infections
      • 5.6.5.1 Global pneumonia or streptococcus associated infections Point of care diagnostics/testing market, 2016 - 2027 (USD Million)
    • 5.6.6 Respiratory syncytial virus (RSV) point of care diagnostics/testing
      • 5.6.6.1 Global respiratory syncytial virus (RSV) point of care diagnostics/testing market, 2016 - 2027 (USD Million)
    • 5.6.7 HPV point of care diagnostics/testing
      • 5.6.7.1 Global HPV point of care diagnostics/testing market, 2016 - 2027 (USD Million)
    • 5.6.8 Influenza/flu point of care diagnostics/testing
      • 5.6.8.1 Global influenza/flu point of care diagnostics/testing market, 2016 - 2027 (USD Million)
    • 5.6.9 HCV point of care diagnostics/testing
      • 5.6.9.1 Global HCV point of care diagnostics/testing market, 2016 - 2027 (USD Million)
    • 5.6.10 MRSA point of care diagnostics/testing
      • 5.6.10.1 Global MRSA point of care diagnostics/testing market, 2016 - 2027 (USD Million)
    • 5.6.11 TB and drug-resistant TB point of care diagnostics/testing
      • 5.6.11.1 Global TB and drug-resistant TB point of care diagnostics/testing market, 2016 - 2027 (USD Million)
    • 5.6.12 HSV point of care diagnostics/testing
      • 5.6.12.1 Global HSV point of care diagnostics/testing market, 2016 - 2027 (USD Million)
    • 5.6.13 Other infectious diseases point of care diagnostics/testing
      • 5.6.13.1 Global other infectious diseases point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • 5.7 Point of care Diagnostics/Testing Cardiac Markers
    • 5.7.1 Global point of care diagnostics/testing cardiac markers market, 2016 - 2027 (USD Million)
  • 5.8 Point of care Diagnostics/Testing Thyroid Testing
    • 5.8.1 Global point of care diagnostics/testing thyroid testing market, 2016 - 2027 (USD Million)
  • 5.9 Hematology Point of care Diagnostics/Testing
    • 5.9.1 Global haematology point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • 5.10 Primary Care Systems
    • 5.10.1 Global primary care systems point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • 5.11 Decentralized clinical chemistry point of care diagnostics/testing
    • 5.11.1 Global decentralized clinical chemistry point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • 5.12 Feces POC Testing
    • 5.12.1 Global feces point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • 5.13 Lipid POC
    • 5.13.1 Global lipid point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • 5.14 Cancer Marker
    • 5.14.1 Global cancer marker testing market, 2016 - 2027 (USD Million)
  • 5.15 Blood Gas/Electrolytes
    • 5.15.1 Global blood gas/electrolytes Point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • 5.16 Ambulatory Chemistry
    • 5.16.1 Global ambulatory chemistry Point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • 5.17 Drug Abuse Point of care Diagnostics/Testing
    • 5.17.1 Global drug abuse point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • 5.18 Urinalysis Point of care Diagnostics/Testing
    • 5.18.1 Global urinalysis Point of care diagnostics/testing market, 2016 - 2027 (USD Million)

Chapter 6 Point of care Diagnostics/ Testing Market: End-use Estimates & Trend Analysis

  • 6.1 Point of care diagnostics/testing market: End-use movement analysis
  • 6.2 Clinics
    • 6.2.1 Global primary care clinics market, 2016 - 2027 (USD Million)
    • 6.2.2 Pharmacy & retail clinicS
      • 6.2.2.1 Global pharmacy & retail clinics market, 2016 - 2027 (USD Million)
    • 6.2.3 Phsician office
      • 6.2.3.1 Global phsician office market, 2016 - 2027 (USD Million)
    • 6.2.4 Urgent care clinics
      • 6.2.4.1 Global urgent care clinics market, 2016 - 2027 (USD Million)
    • 6.2.5 Non-practice clinics
      • 6.2.5.1 Global non-practice clinics market, 2016 - 2027 (USD Million)
  • 6.3 Hospitals
    • 6.3.1 Global hospitals market, 2016 - 2027 (USD Million)
  • 6.4 Home
    • 6.4.1 Global home point of care diagnostics/testing market, 2016 - 2027 (USD Million)
  • 6.5 Assisted Living Healthcare Facilities
    • 6.5.1 Global assisted living healthcare facilities market, 2016 - 2027 (USD Million)
  • 6.6 Laboratory
    • 6.6.1 Global laboratory market, 2016 - 2027 (USD Million)

Chapter 7 Point of care Diagnostics/ Testing Market: Regional Estimates & Trend Analysis for Product & End-use

  • 7.1 Point of care diagnostics/testing market Share by Region, 2019 & 2027
  • 7.2 North America
    • 7.2.1 North America point of care diagnostics/testing market, 2016 - 2027 (USD Million)
    • 7.2.2 U.S.
      • 7.2.2.1 U.S. point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
      • 7.2.2.2 U.S. point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
    • 7.2.3 Canada
      • 7.2.3.1 Canada point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
      • 7.2.3.2 Canada point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
  • 7.3 Europe
    • 7.3.1 Europe point of care diagnostics/testing market, 2016 - 2027 (USD Million)
    • 7.3.2 Germany
      • 7.3.2.1 Germany point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
      • 7.3.2.2 Germany point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
    • 7.3.3 U.K.
      • 7.3.3.1 U.K. point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
      • 7.3.3.2 U.K. point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
    • 7.3.4 France
      • 7.3.4.1 France point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
      • 7.3.4.2 France point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
    • 7.3.5 Italy
      • 7.3.5.1 Italy point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
      • 7.3.5.2 Italy point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
    • 7.3.6 Spain
      • 7.3.6.1 Spain point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
      • 7.3.6.2 Spain point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
    • 7.3.7 Russia
      • 7.3.7.1 Russia point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
      • 7.3.7.2 Russia point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
  • 7.4 Asia Pacific
    • 7.4.1 Asia Pacific point of care diagnostics/testing market, 2016 - 2027 (USD Million)
    • 7.4.2 Japan
      • 7.4.2.1 Japan point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
      • 7.4.2.2 Japan point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
    • 7.4.3 China
      • 7.4.3.1 China point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
      • 7.4.3.2 China point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
    • 7.4.4 India
      • 7.4.4.1 India point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
      • 7.4.4.2 India point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
    • 7.4.5 Australia
      • 7.4.5.1 Australia point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
      • 7.4.5.2 Australia point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
    • 7.4.6 Korea
      • 7.4.6.1 Korea point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
      • 7.4.6.2 Korea point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
    • 7.4.7 Singapore
      • 7.4.7.1 Singapore point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
      • 7.4.7.2 Singapore point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
  • 7.5 Latin America
    • 7.5.1 Latin America point of care diagnostics/testing market, 2016 - 2027 (USD Million)
    • 7.5.2 Brazil
      • 7.5.2.1 Brazil point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
      • 7.5.2.2 Brazil point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
    • 7.5.3 Mexico
      • 7.5.3.1 Mexico point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
      • 7.5.3.2 Mexico point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
    • 7.5.4 Argentina
      • 7.5.4.1 Argentina point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
      • 7.5.4.2 Argentina point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
    • 7.5.5 Chile
      • 7.5.5.1 Chile point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
      • 7.5.5.2 Chile point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
  • 7.6 Middle East & Africa.
    • 7.6.1 Middle East & Africa point of care diagnostics/testing market, 2016 - 2027 (USD Million)
    • 7.6.2 South Africa
      • 7.6.2.1 South Africa point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
      • 7.6.2.2 South Africa point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
    • 7.6.3 Saudi Arabia
      • 7.6.3.1 Saudi Arabia point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
      • 7.6.3.2 Saudi Arabia point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
    • 7.6.4 Kenya
      • 7.6.4.1 Kenya point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
      • 7.6.4.2 Kenya point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
    • 7.6.5 Nigeria
      • 7.6.5.1 Nigeria point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
      • 7.6.5.2 Nigeria point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
    • 7.6.6 Zimbabwe
      • 7.6.6.1 Zimbabwe point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
      • 7.6.6.2 Zimbabwe point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
    • 7.6.7 UAE
      • 7.6.7.1 UAE point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
      • 7.6.7.2 UAE point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)
    • 7.6.8 Qatar
      • 7.6.8.1 Qatar point of care diagnostics/testing market, by product, 2016 - 2027 (USD Million)
      • 7.6.7.2 Qatar point of care diagnostics/testing market, by end use, 2016 - 2027 (USD Million)

Chapter 8 Competitive Landscape

  • 8.1 Company Profile
    • 8.1.1 F. Hoffmann-La Roche Ltd.
      • 8.1.1.1 Company overview
      • 8.1.1.2 Financial performance
      • 8.1.1.3 Product benchmarking
      • 8.1.1.4 Strategic initiatives
    • 8.1.2 Abbott
      • 8.1.2.1 Company overview
      • 8.1.2.1.1 Alere, Inc.
      • 8.1.2.2 Financial performance
      • 8.1.2.3 Product benchmarking
      • 8.1.2.4 Strategic initiatives
    • 8.1.3 Siemens
      • 8.1.3.1 Company overview
      • 8.1.3.2 Financial performance
      • 8.1.3.3 Product benchmarking
      • 8.1.3.4 Strategic initiatives
    • 8.1.4 Danaher
      • 8.1.4.1 Company overview
      • 8.1.4.1.1 Beckman Coulter, Inc.
      • 8.1.4.1.2 Radiometer Medical ApS
      • 8.1.4.1.3 HemoCue AB
      • 8.1.4.2 Financial performance
      • 8.1.4.3 Product benchmarking
      • 8.1.4.4 Strategic initiatives
    • 8.1.5 bioMerieux SA
      • 8.1.5.1 Company overview
      • 8.1.5.2 Financial performance
      • 8.1.5.3 Product benchmarking
      • 8.1.5.4 Strategic initiatives
    • 8.1.6 Johnson & Johnson
      • 8.1.6.1 Company overview
      • 8.1.6.2 Financial performance
      • 8.1.6.3 Product benchmarking
      • 8.1.6.4 Strategic initiatives
    • 8.1.7 Abaxis, Inc.
      • 8.1.7.1 Company overview
      • 8.1.7.2 Financial performance
      • 8.1.7.3 Product benchmarking
      • 8.1.7.4 Strategic initiatives
    • 8.1.8 QIAGEN
      • 8.1.8.1 Company overview
      • 8.1.8.2 Financial performance
      • 8.1.8.3 Product benchmarking
      • 8.1.8.4 Strategic initiatives
    • 8.1.9 Instrumentation Laboratory
      • 8.1.9.1 Company overview
      • 8.1.9.2 Accriva Diagnostics
      • 8.1.9.3 Financial performance
      • 8.1.9.4 Product benchmarking
      • 8.1.9.5 Strategic initiatives
    • 8.1.10 Nova Biomedical
      • 8.1.10.1 Company overview
      • 8.1.10.2 Financial performance
      • 8.1.10.3 Product benchmarking
      • 8.1.10.4 Strategic initiatives
    • 8.1.11 Trividia Health, Inc.
      • 8.1.11.1 Company overview
      • 8.1.11.2 Financial performance
      • 8.1.11.3 Product benchmarking
      • 8.1.11.4 Strategic initiatives
    • 8.1.12 Quidel Corporation
      • 8.1.12.1 Company overview
      • 8.1.12.2 Financial performance
      • 8.1.12.3 Product benchmarking
      • 8.1.12.4 Strategic initiatives
    • 8.1.13 Trinity Biotech
      • 8.1.13.1 Company overview
      • 8.1.13.2 Financial performance
      • 8.1.13.3 Product benchmarking
      • 8.1.13.4 Strategic initiatives
    • 8.1.14 Sekisui Diagnostics LLC
      • 8.1.14.1 Company overview
      • 8.1.14.2 Financial performance
      • 8.1.14.3 Product benchmarking
      • 8.1.14.4 Strategic initiatives
    • 8.1.15 OraSure Technologies Inc.
      • 8.1.15.1 Company overview
      • 8.1.15.2 Financial performance
      • 8.1.15.3 Product benchmarking
      • 8.1.15.4 Strategic initiatives
    • 8.1.16 Becton Dickinson & Company (BD)
      • 8.1.16.1 Company overview
      • 8.1.16.2 Financial performance
      • 8.1.16.3 Product benchmarking
      • 8.1.16.4 Strategic initiatives
    • 8.1.17 Nipro Diagnostics Inc.
      • 8.1.17.1 Company overview
      • 8.1.17.2 Financial performance
      • 8.1.17.3 Product benchmarking
      • 8.1.17.4 Strategic initiatives
    • 8.1.18 Spectral Medical, Inc.
      • 8.1.18.1 Company overview
      • 8.1.18.2 Financial performance
      • 8.1.18.3 Product benchmarking
      • 8.1.18.4 Strategic initiatives